The top pre-market NASDAQ Stock Market gainers are: Opnext, Acorda Therapeutics, Red Robin Gourmet, BioSante Pharmaceuticals, STEC, AEterna Zentaris and Human Genome Sciences. The top pre-market NASDAQ Stock Market losers are: Popular, Nordson and Immunogen.
Opnext, Inc. (NASDAQ:OPXT) shares climbed 21.39 percent to $2.25 pre-market trading session. The company swung to fourth quarter net income of $9.04 million or $0.10 per share compared to a loss of $18.30 million or $0.20 last year. Adjusted loss narrowed to $8.75 million or $0.10 per share from $14.52 million or $0.16 per share. Revenue rose to $95.35 million from $76.78 million. Analysts had expected a loss of $0.09 per share on revenue of $96.27 million. For the first quarter, the company expects revenue of $93 million to $97 million, while Street predicts $95.85 million.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares surged 20.18 percent to $32.10 in pre-market trading session.
Red Robin Gourmet Burgers Inc. (NASDAQ:RRGB) shares jumped jumped 19.21 percent to $34.00 in pre-market trading session. Adjusted earnings for the first quarter was $9.02 million or $0.58 per share, higher than $2.31 million or $0.15 per share last year. Revenue rose to $286.83 million from $275.51 million. Analysts had expected a profit of $0.25 per share on revenue of $283.49 million. Comparable restaurant sales increased 1.9 percent for company-owned restaurants. Comparable sales for franchise restaurants in the U.S. increased 2.5 percent and for franchise restaurants in Canada decreased 1.2 percent.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) shares surged 6.57 percent to $2.61 in pre-market trading session. The stock has a 52 week low of $1.29 and 52 week high of $2.69 and has $229.20 million market capitalization.
STEC, Inc. (NASDAQ:STEC) shares advanced 5.4 percent to $15.52 in the pre-market trading session.
AEterna Zentaris, Inc. (NASDAQ:AEZS) shares advanced 4.23 percent to $2.22 in pre-market trading session.
Human Genome Sciences, Inc. (NASDAQ:HGSI) shares advanced 3.65 percent to $29.00 in pre-market trading session. The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has issued a positive opinion, recommending marketing authorisation for BENLYSTA, as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity, despite standard therapy.
Popular Inc. (NASDAQ:BPOP) shares declined 5.94 percent to $2.85 in the pre-market trading. The company said Banco Popular de Puerto Rico, its principal banking subsidiary, and a financial group led by an unrelated real estate investment and asset management firm had terminated negotiations regarding the sale by Banco Popular de Puerto Rico of a portfolio of non-performing construction and commercial real estate loans to a new joint venture entity to be sponsored by the financial group.
The negotiations were terminated as a result of the parties being unable to agree on the final terms and conditions of the definitive documentation, the company said. On January 31, Popular had announced the execution of a non-binding letter of intent regarding this transaction. The company said it would continue to explore other opportunities to sell these assets in one or more transactions, as well as internal strategies to maximize its recoveries.
Nordson Corp. (NASDAQ:NDSN) shares declined 5.39 percent to $51.48 in pre-market trading. The company expects third quarter earnings of $0.84 to $0.91 per share and sales of $315 million to $326 million, while Street predicts profit of $0.88 per share on revenue of $328.75 million. Nordson reported second quarter earnings of $65.2 million or $0.95 per share, up from $32.4 million or $0.47 per share last year. Sales grew 27 percent to $319.0 million. Analysts had expected profit of $0.88 per share on revenue of $319.96 million for the second quarter.
Immunogen Inc. (NASDAQ:IMGN) shares declined 5.34 percent to $12.05 in pre-market trading. The company said it plans to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company, Inc. is acting as the sole book-running manager for the proposed offering and Oppenheimer & Co. Inc., RBC Capital Markets, LLC, William Blair & Company, LLC, Canaccord Genuity Inc. and Morgan Joseph TriArtisan LLC are acting as co-managers.